Nevro announces enrollment of first patient in PDN sensory study

Nevro "announced that it has enrolled the first patient in its Painful Diabetic Neuropathy Sensory Study, which is the first prospective randomized controlled trial to assess restoration of neurological function as a primary objective in patients with intractable PDN. The study will enroll up to 236 patients at multiple sites across the U.S. Patients will be randomized to conventional medical management or 10 kHz Therapy plus conventional medical management, with optional crossover to the other treatment arm at 6 months if those criteria are met."